CEBPB and ovarian carcinoma: Importantly, we have previously reported that bexarotene-dependent inhibition of NRF2 lowered expression of HER2 and HER3 receptors and enhanced the cytotoxicity of ERL and LAP in ovarian cancer cells [40].